Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Exanthema × capivasertib × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6 Triple Negative Breast Neoplasms 2 Recurrence 1 Prostatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasms 1 Neoplasm Metastasis 1 Meningioma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Exanthema 1 Diarrhea 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1 Advanced Gastric Cancer 1 Advanced Breast Cancer 1 Adenocarcinoma 1

Interventions

Fulvestrant 2 ruxolitinib 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Sirolimus 1 Prednisone 1 Panitumumab 1 Loperamide 1 Irinotecan 1 IFL protocol 1 Gels 1 Doxycycline 1 Dapsone 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07426822 2026-02-24

SAFE-CAP

Yale University

Phase 2 Not yet recruiting

Diarrhea, Exanthema

Data powered by HemOnc (CC BY 4.0) Colophon ⚡